Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Includes thermostabilized Ebola vaccines
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
This is the first major brand refresh of CanSinoBIO since its inception in 2009
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
The goal for the project is the identification and optimization of anti-viral compounds.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)